Applied Biosciences Corp. · OTC:APPB
Applied Biosciences — Investor Presentation (October 2019)
30 slides from Applied Biosciences's investor presentation, Oct 28, 2019
Slide 1: Corporate Overview October 2019
e |APPLIED °.| BIOSCIENCES Corporate Overview October 2019
Slide 2: Forward Looking Statements
\ Forward Looking Statements ‘Statements in this presentation may be “fonwarélocking statements” within the meaning ofthe Private Secures Ligation Reform Act of 1995. Words such as “anticipate, “bollove’, “estimate, "expect, “intend”, and similar expressions, as they relate to the Company or lis man
Slide 3: Corporate Overview
APPLIED cused on the development of science-driven biopharmaceuticals and the production high-quality health & welins products that target the endocannabinoid system \ Corporate Overview Biopharmaceuticals: Developing a pipeine of well veted endocannabinoid system-rgeted drug ‘candidates in igh-valu
Slide 4: Corporate Structure
ses, QS Corporate Structure APPLIED BIOSCIENCES AAPPLIED ‘Apples Subscary
Slide 5: Leadership Team
Pen \ Leadership Team of the Board Raymond W Urbanski M.D., Ph.D. Chiat Executive Officer & Director ‘Welton nduty leaig tier and maatonal seca ith oer 20 {for of erperenesin ha prammacsttal sastosch sacs neag a rarest RAD cel developmen and mas afar else Paice ey rn eas ene a od ‘Schroeder Presiden
Slide 6: Applied BioPharma: Science-Driven Synthetic Therapeutics Targeting the Endocannabinoid System
| APPLIED BIOPHARMA NN. Science-Driven Synthetic Therapeutics Targeting the Endocannabinoid System
Slide 7: Applied BioPharma Overview
Applied BioPharma Overview Leveraging an Industry-Leading Pipeline of Endocannabinoid System-Targeted Drug Candidates Optimization of lead scaffolds guided by advanced computational ‘methods resulting in numerous risk-reduced drug candidates Lead CB2 Inverse Agonist ExPect to advance preclinical pro
Slide 8: The Endocannabinoid System (ECS)
The Endocannabinoid System (ECS) Major Homeostatic, System in the Body Made up of wo primary G-protein ‘coupled receptors Modulates ce, activity of CB, ‘systems in ‘he body Central Nervous System (CNS) oboe an Peripheral (Rest of Body) el eee ce & eS ones a
Slide 9: ECS-Targeting Drug Discovery Platform
A VSEPL ES \ ECS-Targeting Drug Discovery Platform Leveraging novel therapeutic approaches to regulate the pathophysiologic reactions and homeostatic imbalances which underlie the initiation, progression, and exacerbation of disorders such as ocular injury, traumatic brain injury, acute and chronic
Slide 10: Building a Leading ECS-Targeting Pipeline
Building a Leading ECS-Targeting Pipeline — Advanced Discussions Underway to Fuel Pipeline APPLIED world-renowned academic centers and organizations Working with Bringing ECS-targeting additional assets Metaboe Diseases | ttammatany Lung Oieenes | Chemo induced Periheral Neuropathy Program Therapeut
Slide 11: ABP-1901: Lead CB2 Inverse Agonist
ABP-1901: Lead CB2 Inverse Agonist Lead Program in Development for Treatment of Mild Traumatic Brain Injury Targeting the ECS brain edema (AAPPLIED
Slide 12: Preclinical Study Results
se, Na Preclinical Study Results fOSCIENCES Extensively Studied in Animal Models of mTBI and Ocular Injury'S
Slide 13: ABP-1902: CB2 Agonist
ens, 902: CB2 Agonist fOSCIENCES Lead Program in Development for Treatment of Acute Kidney Injury Targeting the ECS AAPPLIED (4
Slide 14: ABP-1902: AKI Ischemia/Reperfusion Model
ABP-1902: AKI Ischemia/Reperfusion Model Promising Preclinical Results Demonstrating Reduction in Kidney Damage ABP-1902 Increased steady-state levels 4) of CB2 receptor MRNA levels + Reduces tubular epithelial damage after renal é ischemia-teperfusion injur 3 ed protection of the renal tubular hell
Slide 15: Scientific Advisory Board
Scientific Advisory Board Judith Korner M.0., Ph.D. iow York Preshyerar! Cole Unversity Matic! Center ‘tse hen Yor Peseaan’ Cuma ge Cant Ur fae ‘eons nes tage he Cll ser Spare ol Care ‘Seat srs au tases he uD tea antes Base llr cB tho. Sm area rai an ose ‘ies sn Seto cod organs Patricia Reggio Ph.D.
Slide 16: Applied Products: CBD Therapies
Applied Products: CBD Therapies NN.
Slide 17: Applied Products: CBD Product Overview
Applied Products: CBD Product Overview At the forefront Address ailments Full line of of Health de! in multiple pet remedie and Wellness eae | CaN
Slide 18: $16bn Total Market Potential by 2025
+ $16bn Total Market Potential by 2025 with 35% CAGR + Current products on the Bn market and are not high quality or are not what they say they are ‘dads.
Slide 19: The 'Applied' Quality Difference
A VSEPL ES \ The ‘Applied’ Quality Difference Utlizes the most proven and effective production methods 0, Extraction and winterzation process alows forthe proper retention of cannabinoids and terpenes vs a distilate THC Free products are CBD Isolate infused, leaving behind pure pharmaceutical grade
Slide 20: Brands & Distributed Products
siesute, NGS Brands & Distributed Products doe) Ahebopete =NAMAH (aa @ EquineCare Sagoron pendtech
Slide 21: CBD Products: Consumer
CBD Products: Consumer Creams Gummies Capsules Tinctures apes herbolpet
Slide 22: CBD Products: Sports Medicine - Launch of New Product Line
CBD Products: Sports Medicine - Launch of New (eames Product Line
Slide 23: Trace Analytics
Slide 24: CBD Testing & Analytics
\ CBD Testing & Analytics Scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing State & Local STamaces Growers, Cooperatives, Manufacturing, Distributors, Retailers, End Users Performing Regulatory, Process & Cultivation Sc
Slide 25: Corporate Overview
Corporate Overview
Slide 26: Corporate Strategy
ayes \ Corporate Strategy Applied BioPharma * Bld out BioPharma group through Key hires, advisors and strategie partnerships + Put into place requisite intemal infrastructure fo support running multiple programs simultaneously + Indicense wel vetted, science-criven assets addressing diverse indicati
Slide 27: Capitalization Table — June 30, 2019
; \ Capitalization Table — June 30, 2019 APPLIED Common Stock Outstanding 1344713 Directors and Officers 3672124 Beneficial Owners 3,085,000 +The Company currently has All Other Shareholders 6,719.89 200,000,000 commen shares and 5,000,000 preferred Shares tobe issued 359,805 shares authorized Equit
Slide 28: Milestones Expected to Drive Value
conse No Milestones Expected to Drive Value fosciences CBD Products Trace Analytics AAPPLIED
Slide 29: Compelling Investment Opportunity
‘Management Assets, a) Finance \ Compelling Investment Opportunity ‘Atrack record of success in the biotech and large pharma space across ‘multiple functions Extensive experience bulding successful companies and organizations + Extensive experience in all phases of drug development — know what to do
Slide 30: Applied BioSciences Corporate Overview
APPLIED BIOSCIENCES Corporate Overview
Applied BioSciences — Investor Presentation (October 2019) on 6ix